| 1 |
35455642 | Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting. | 2022 Mar 24 |
3 |
| 2 |
33808367 | Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase. | 2021 Mar 30 |
1 |
| 3 |
31945490 | Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban. | 2020 Mar |
2 |
| 4 |
32336024 | Supratheraputic rivaroxaban levels: A persistent drug-drug interaction after discontinuation of amiodarone. | 2020 Oct |
2 |
| 5 |
32887180 | Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. | 2020 Sep 4 |
2 |
| 6 |
32975202 | Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. | 2020 Sep 4 |
2 |
| 7 |
33276942 | Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. | 2020 Nov |
1 |
| 8 |
29773500 | An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1). | 2018 Aug |
1 |
| 9 |
26608490 | [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease]. | 2015 Oct |
2 |
| 10 |
23663291 | Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. | 2013 Oct |
2 |
| 11 |
22270945 | Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. | 2012 Mar |
1 |